Xanthine oxidase-IN-4 (compound 19a) is an orally active and potent xanthine oxidase (XO) inhibitor with an IC50 of 0.039 μM, suitable for research in hyperuricemia and gout. Xanthine oxidase-IN-4 demonstrates hypouricemic potency in potassium oxonate-induced hyperuricemia rats. [1].

Xanthine oxidase-IN-4 (compound 19a) exhibits significant inhibitory activity against xanthine oxidase, with an IC50 of 0.039 μM and a Ki of 0.0037 μM, across concentrations from 1 nM to 10 μM over 15 minutes [1].

Xanthine oxidase-IN-4 (compound 19a), administered intragastrically at 10 mg/kg to male Sprague-Dawley rats (six weeks old, 180-200g, divided into six groups), significantly reduced serum uric acid concentration, with a quantified 44.3% reduction in the area under the curve (AUC) for serum uric acid levels measured between 1 and 5 hours post-dose.